Advertisement!
44.210.21.70
For Authors
Editorial Board
Submit article
Editor's selection process
Join as Reviewer/Editor
List of Reviewer
Indexing Information
Most popular articles
Open Access
Purchase Single Articles
Archive
Current Issue
Recommend this journal to your library
Advertiser
Accepted Articles
Search Articles
Email Alerts
Subscribe
FAQ
Contact Us
Urology, Nephrology and Andrology International

Volume  7, Issue 1, January-June 2022, Pages 7-13

 

Original Article

Is Combination Therapy (Mirabegron + Solifenacin) better than Monotherapy (Solifenacin) in the Treatment of OAB?
SML Prakash Babu1, Abhishek Kulkarni2, Sangle Ameya Rangnath3
Associate Professor, 2Consultant Urologist, 3Senior Resident, Department of Urology, MS Ramaiah Medical College, Bangalore 560054, Karnataka, India.
Choose an option to locate / access this Article:
Check if you have access through your login credentials.             |
|

http://dx.doi.org/10.21088/unai.2456-5016.7122.1

Abstract

OAB is a common and distressing chronic bladder condition presenting
with symptoms of urinary frequency, urgency, and urge incontinence.
Pharmacotherapy with antimuscarinic agents is one of the major treatment
options for OAB. Mirabegron in combination with antimuscarinic drugs is being
used for treatment-resistant OAB. Given that the two groups have different
modes of action, it is logical to think that combination therapy would have
advantages over monotherapy
 


Corresponding Author : Sangle Ameya Rangnath